Poziotinib Completed Phase 2 Trials for Breast Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02659514Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer